{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD). The G2019S mutation is associated with familial and non-familial cases.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Assays include binding assays and in vitro kinase activity assays.",
          "judgment": "Yes",
          "reasoning": "The assays directly assess kinase activity, which is central to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "G2019S has higher kinase activity and altered ATP affinity.",
          "judgment": "Yes",
          "reasoning": "The assays used are standard for assessing kinase function, but the paper does not explicitly mention controls or replicates beyond what is implied."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "G2019S is more sensitive to ATP-competitive inhibitors than wild-type.",
          "judgment": "Yes",
          "reasoning": "The functional data supports the pathogenicity of G2019S."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "G2019S is associated with increased kinase activity and altered ATP affinity, supporting its pathogenic role in PD."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD). The I2020T mutation alters kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Assays include binding assays and in vitro kinase activity assays.",
          "judgment": "Yes",
          "reasoning": "The assays directly assess kinase activity, which is central to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "I2020T has lower ATP affinity and altered kinase activity.",
          "judgment": "Yes",
          "reasoning": "The assays used are standard for assessing kinase function, but the paper does not explicitly mention controls or replicates beyond what is implied."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "I2020T is more resistant to ATP-competitive inhibitors than wild-type.",
          "judgment": "Yes",
          "reasoning": "The functional data supports the pathogenicity of I2020T."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "I2020T is associated with altered kinase activity and ATP affinity, supporting its pathogenic role in PD."
    }
  ]
}